Photosensitizers and light sources for photodynamic therapy of the Bowen’s disease

被引:0
作者
M. A. Calin
A. Diaconeasa
D. Savastru
M. Tautan
机构
[1] National Institute of Research and Development for Optoelectronics INOE 2000,Department of Dermatology
[2] Grigore Alexandrescu Hospital,undefined
来源
Archives of Dermatological Research | 2011年 / 303卷
关键词
Bowen’s disease; Light; Photosensitizer; Photodynamic treatment;
D O I
暂无
中图分类号
学科分类号
摘要
Bowen’s disease is a neoplastic skin disease, known as squamous cell carcinoma in situ. The treatment options for Bowen’s disease are: cryotherapy, curettage, surgery, topical therapy and radiotherapy. In the past recent years, photodynamic therapy was used as a new treatment method. The purpose of this paper is to summarize the results of clinical and research studies with respect to the photodynamic therapy of Bowen’s disease. A search of three databases was conducted using specific keywords and explicit inclusion and exclusion criteria for the study of photosensitizers, light sources and their efficacy in photodynamic therapy of Bowen’s disease. Two photosensitizers have been used mainly for photodynamic therapy of Bowen’s disease therapy: δ-aminolevulinic acid and methyl aminolevulinate. These photosensitizers have been activated with both coherent (lasers) and non-coherent (lamps and LEDs) light sources. Fluence has been set in a large domain (10–240 J/cm2) and irradiance was 0.23–100 mW/cm2. All these light sources have the same efficacy. The high response rates were obtained using methyl aminolevulinate and light emitting diode as light source. These results have demonstrated that photodynamic therapy using methyl aminolevulinate as photosensitizer could be considered as one of the first therapeutic options for Bowen’ disease.
引用
收藏
页码:145 / 151
页数:6
相关论文
共 94 条
[1]  
Attili SK(2009)10.1111/j.1365-2133.2009.09096.x 10 Br J Dermatol 161 170-173
[2]  
Lesar A(2005)Investigation of the use of the pulsed dye laser in the treatment of Bowen’s disease using 5-aminolaevulinic acid phototherapy Br J Dermatol 153 780-784
[3]  
McNeill A(2008)Methylaminolaevulinate-based photodynamic therapy of Bowen’s disease and squamous cell carcinoma Br J Dermatol 159 137-144
[4]  
Camacho-Lopez M(2003)Topical 5-aminolaevulinic acid photodynamic therapy for cutaneous lesions: outcome and comparison of light sources Photodermatol Photoimmunol Photomed 19 134-141
[5]  
Moseley H(1999)Guidelines for management of Bowen’s disease Br J Dermatol 141 633-641
[6]  
Ibbotson S(2008)The value of photodynamic therapy in the treatment of Bowen’s disease Ann Dermatol Venereol 135 822-827
[7]  
Samuel IDW(1987)Photosensitizers: therapy and detection of malignant tumors Photochem Photobiol 45 879-889
[8]  
Ferguson J(2008)Pathologic changes after photodynamic therapy for basal cell carcinoma and Bowen disease Arch Dermatol 144 186-194
[9]  
Britton JE(1996)Influence of topical photodynamic therapy with 5-aminolevulinic acid on porphyrin metabolism Arch Dermatol Res 288 517-521
[10]  
Goulden V(2009)Fractionated aminolevulinic acid–photodynamic therapy provides additional evidence for the use of PDT for non-melanoma skin cancer J Eur Acad Dermatol Venereol 23 571-572